The estimated Net Worth of Jakob Haldor Topsoe is at least $1.1 Milion dollars as of 29 June 2023. Mr. Topsoe owns over 7,000 units of IGM Biosciences stock worth over $958,501 and over the last 5 years he sold IGMS stock worth over $0. In addition, he makes $137,194 as Independent Director at IGM Biosciences.
Sign up
Mr. Topsoe IGMS stock SEC Form 4 insiders trading
Jakob has made over 7 trades of the IGM Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of IGMS stock worth $64,190 on 29 June 2023.
The largest trade he's ever made was buying 1,285,475 units of IGM Biosciences stock on 18 September 2019 worth over $20,567,600. On average, Jakob trades about 44,985 units every 43 days since 2019. As of 29 June 2023 he still owns at least 81,644 units of IGM Biosciences stock.
You can see the complete history of Mr. Topsoe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jakob Topsoe biography
Jakob Haldor Topsoe serves as Independent Director of the Company. Mr. Topsøe has served as Chairman of the board of directors of Haldor Topsøe Holding A/S (HTH), and has served on the board of directors of Haldor Topsøe A/S, a Danish catalysis and chemical processing company and a subsidiary of HTH, since October 2010 and as its Vice Chairman since August 2016. Since January 2009, Mr. Topsøe has served as Partner at AMBROX Capital, a Danish investment management firm, and as Associate Partner since September 2016. From 1996 to 2008, Mr. Topsøe was employed in various functions within Alfred Berg/ABN Amro Bank including Head of Equities, Denmark. Mr. Topsøe currently serves as a member of the board of directors of Motortramp, a Danish provider of marine transportation services, and Dampskibsselskabet Orients Fond, a Danish charitable foundation. Mr. Topsøe received a Graduate Diploma in Business Administration (Finance) from the Copenhagen Business School.
What is the salary of Jakob Topsoe?
As the Independent Director of IGM Biosciences, the total compensation of Jakob Topsoe at IGM Biosciences is $137,194. There are 14 executives at IGM Biosciences getting paid more, with Fred M. Schwarzer J.D. having the highest compensation of $926,901.
How old is Jakob Topsoe?
Jakob Topsoe is 51, he's been the Independent Director of IGM Biosciences since 2018. There are 12 older and 7 younger executives at IGM Biosciences. The oldest executive at IGM Biosciences, Inc. is Michael Loberg, 72, who is the Independent Chairman of the Board.
What's Jakob Topsoe's mailing address?
Jakob's mailing address filed with the SEC is C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW, CA, 94043.
Insiders trading at IGM Biosciences
Over the last 5 years, insiders at IGM Biosciences have traded over $2,263,330 worth of IGM Biosciences stock and bought 10,358,723 units worth $195,788,133 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... a Bros. Advisors Lp667, L.P.B.... On average, IGM Biosciences executives and independent directors trade stock every 13 days with the average trade being worth of $942,182. The most recent stock trade was executed by Julie Hambleton on 25 July 2024, trading 15,132 units of IGMS stock currently worth $21,033.
What does IGM Biosciences do?
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
What does IGM Biosciences's logo look like?
Complete history of Mr. Topsoe stock trades at IGM Biosciences
IGM Biosciences executives and stock owners
IGM Biosciences executives and other stock owners filed with the SEC include:
-
Fred M. Schwarzer J.D.,
CEO, Pres & Director -
Fred Schwarzer,
President, Chief Executive Officer, Director -
Dr. Shinyu Chen M.D., Ph.D.,
Consultant -
Dr. Chris H. Takimoto FACP, M.D., Ph.D.,
Chief Medical Officer -
Dr. Bruce A. Keyt,
Chief Scientific Officer -
Fred M. Schwarzer,
CEO, Pres & Director -
Bruce Keyt,
Chief Scientific Officer -
Misbah Tahir,
Chief Financial Officer -
Michael Loberg,
Independent Chairman of the Board -
M. Kathleen Behrens,
Independent Director -
Julie Hambleton,
Independent Director -
William Strohl,
Independent Director -
Christina Topsoe,
Independent Director -
Kelvin Neu,
Independent Director -
Jakob Topsoe,
Independent Director -
Michael Lee,
Independent Director -
David Pitts,
IR Contact Officer -
Daniel Chen,
Chief Medical Officer -
Steven Weber,
SVP, Corp. Controller & Principal Accounting Officer -
Marvin S. Peterson Ph.D.,
Sr. VP, Process Sciences & Manufacturing -
George A. Gauthier,
Chief Commercial Officer -
Dr. Lisa L. Decker Ph.D.,
Chief Bus. Officer -
Misbah Tahir,
Chief Financial Officer -
Angus Sinclair,
VP of Immuno-Oncology -
Suzette Tauber,
VP of HR -
Paul C. Graffagnino,
VP of Legal Affairs -
Mary Beth Harler,
Head, Research & Autoimmunity -
Group, Llc Green Jeremy Red...,
-
Bros. Advisors Lp667, L.P.B...,
-
Holding A/S Topsoe,
10% owner -
Chris H Takimoto,
CHIEF MEDICAL OFFICER -
Bros. Advisors Lp667, L.P.B...,
-
Lisa Lynn Decker,
CHIEF BUSINESS OFFICER -
George Gauthier,
Chief Commercial Officer -
Steven Weber,
PRINCIPAL ACCOUNTING OFFICER -
Elizabeth H.Z. Thompson,
-
Bros. Advisors Lp667, L.P.B...,